Literature DB >> 7804940

Hepatitis B vaccination and screening for markers at a sexually transmitted disease clinic for men.

L Yuan1, G Robinson.   

Abstract

In Ontario, persons with multiple sexual partners became eligible for free hepatitis B vaccine in late 1991. From January 1992 to January 1993, a sexually transmitted disease (STD) clinic for men in Toronto was one site where the vaccine was delivered. The objectives of the study were to determine the seroprevalence of hepatitis B markers, the series completion rate for hepatitis B vaccine, and the seroprevalence of hepatitis B markers required before screening would be a cost-effective endeavour. The seroprevalence of anti-HBs in gay/bisexual men was 18.1% (95% CI: 15.3%-20.7%) and in heterosexual men was 5.1% (95% CI: 3.0-9.7%). HBsAg was detected in 0.9% (95% CI: 0.04%-1.8%) of gay/bisexual men and was undetected in heterosexual men. Completion of a full vaccine series was 47% for gay/bisexual men and 25% for heterosexual men (p = 0.04). A combined seroprevalence of HBsAg and anti-HBs of at least 30-64%, depending on cost figures used, was required to justify screening prior to completion of a full series.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7804940

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  6 in total

Review 1.  Understanding correlates of hepatitis B virus vaccination in men who have sex with men: what have we learned?

Authors:  L J Yee; S D Rhodes
Journal:  Sex Transm Infect       Date:  2002-10       Impact factor: 3.519

2.  Association of hepatitis B virus infection with other sexually transmitted infections in homosexual men. Omega Study Group.

Authors:  R S Remis; A Dufour; M Alary; J Vincelette; J Otis; B Mâsse; B Turmel; R LeClerc; R Parent; R Lavoie
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

3.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

4.  Prevalence and risk factors for hepatitis B virus infections among visitors to an STD clinic.

Authors:  Y T van Duynhoven; M J van de Laar; W A Schop; P H Rothbarth; W I van der Meijden; A M van Loon; M J Sprenger
Journal:  Genitourin Med       Date:  1997-12

5.  Chronic hepatitis B infection in Canada.

Authors:  G Y Minuk; J Uhanova
Journal:  Can J Infect Dis       Date:  2001-11

6.  An economic assessment of pre-vaccination screening for hepatitis A and B.

Authors:  R Jake Jacobs; Sammy Saab; Allen S Meyerhoff; Raymond S Koff
Journal:  Public Health Rep       Date:  2003 Nov-Dec       Impact factor: 2.792

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.